Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

4,525 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Differential effect of low-dose aspirin for primary prevention of atherosclerotic events in diabetes management: a subanalysis of the JPAD trial.
Okada S, Morimoto T, Ogawa H, Kanauchi M, Nakayama M, Uemura S, Doi N, Jinnouchi H, Waki M, Soejima H, Sakuma M, Saito Y; Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes Trial Investigators. Okada S, et al. Diabetes Care. 2011 Jun;34(6):1277-83. doi: 10.2337/dc10-2451. Epub 2011 Apr 22. Diabetes Care. 2011. PMID: 21515838 Free PMC article. Clinical Trial.
Low-dose aspirin therapy in patients with type 2 diabetes and reduced glomerular filtration rate: subanalysis from the JPAD trial.
Saito Y, Morimoto T, Ogawa H, Nakayama M, Uemura S, Doi N, Jinnouchi H, Waki M, Soejima H, Sugiyama S, Okada S, Akai Y; Japanese Primary Prevention of Atherosclerosis With Aspirin for Diabetes Trial Investigators. Saito Y, et al. Among authors: okada s. Diabetes Care. 2011 Feb;34(2):280-5. doi: 10.2337/dc10-1615. Diabetes Care. 2011. PMID: 21270185 Free PMC article. Clinical Trial.
Aspirin reduces cerebrovascular events in type 2 diabetic patients with poorly controlled blood pressure. Subanalysis from the JPAD trial.
Soejima H, Ogawa H, Morimoto T, Nakayama M, Okada S, Uemura S, Kanauchi M, Doi N, Sakuma M, Jinnouchi H, Sugiyama S, Waki M, Saito Y; JPAD Trial Investigators. Soejima H, et al. Among authors: okada s. Circ J. 2012;76(6):1526-32. doi: 10.1253/circj.cj-11-1033. Epub 2012 Mar 23. Circ J. 2012. PMID: 22447019 Free article. Clinical Trial.
[109th Scientific Meeting of the Japanese Society of Internal Medicine: symposium: 2. Translational research and evidence-based medicine (EBM) in internal medicine in Japan, EBM; 1) How to understand the results of randomized controlled trials for primary prevention of cardiovascular events in patients with diabetes mellitus: Lesson from the JPAD trial].
Saito Y, Okada S, Ogawa H, Soejima H, Morimoto T, Sakuma M; JPAD Investigators. Saito Y, et al. Among authors: okada s. Nihon Naika Gakkai Zasshi. 2012 Sep 10;101(9):2563-70. doi: 10.2169/naika.101.2563. Nihon Naika Gakkai Zasshi. 2012. PMID: 23205435 Clinical Trial. Japanese. No abstract available.
An elevated ratio of placental growth factor to soluble fms-like tyrosine kinase-1 predicts adverse outcomes in patients with stable coronary artery disease.
Matsumoto T, Uemura S, Takeda Y, Matsui M, Okada S, Nishida T, Soeda T, Okayama S, Somekawa S, Ishigami K, Onoue K, Kawata H, Kawakami R, Horii M, Saito Y. Matsumoto T, et al. Among authors: okada s. Intern Med. 2013;52(10):1019-27. doi: 10.2169/internalmedicine.52.9073. Epub 2013 May 15. Intern Med. 2013. PMID: 23676585 Free article. Clinical Trial.
Aspirin possibly reduces cerebrovascular events in type 2 diabetic patients with higher C-reactive protein level: subanalysis from the JPAD trial.
Soejima H, Ogawa H, Morimoto T, Nakayama M, Okada S, Sakuma M, Uemura S, Kanauchi M, Doi N, Jinnouchi H, Sugiyama S, Waki M, Saito Y; JPAD Trial Investigators. Soejima H, et al. Among authors: okada s. J Cardiol. 2013 Sep;62(3):165-70. doi: 10.1016/j.jjcc.2013.03.015. Epub 2013 Jun 16. J Cardiol. 2013. PMID: 23778008 Free article. Clinical Trial.
Comparison between angiotensin-converting enzyme inhibitors and angiotensin receptor blockers on the risk of stroke recurrence and longitudinal progression of white matter lesions and silent brain infarcts on MRI (CEREBRAL study): rationale, design, and methodology.
Yamano S, Horii M, Takami T, Sakuma M, Morimoto T, Okada S, Taoka T, Kichikawa K, Sasamura H, Itoh H, Furuya Y, Ueno S, Imamura T, Sugiyama S, Ogawa H, Saito Y. Yamano S, et al. Among authors: okada s. Int J Stroke. 2015 Apr;10(3):452-6. doi: 10.1111/ijs.12085. Epub 2013 Jul 9. Int J Stroke. 2015. PMID: 23834197 Clinical Trial.
4,525 results